Aquestive Therapeutics (AQST)

• Market cap: $321M
• 1 day: -1.95%
• 5 days: -9.51%
• 1 month: -26.82%
• 3 months: -30.16%
• 6 months: 44.86%
• Year to date: 75.12%
• 1 year: 76.00%
• 5 years: -39.31%
• 10 years: -78.07%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Sympazan Oral Film, Suboxone Sublingual Film, Exservan Oral Film, and Zuplenz. The product pipeline includes Libervant Buccal Film, AQST-108, and AQST-305. The majority of its revenue comes from the United States.

Employees: 135

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

358% more call options, than puts

Call options by funds: $5.75M | Put options by funds: $1.26M

111% more first-time investments, than exits

New positions opened: 40 | Existing positions closed: 19

108% more capital invested

Capital invested by funds: $112M [Q2] → $232M (+$120M) [Q3]

65% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 23

22% more funds holding

Funds holding: 96 [Q2] → 117 (+21) [Q3]

4.09% more ownership

Funds ownership: 47.27% [Q2] → 51.37% (+4.09%) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 2 [Q2] → 2 (+0) [Q3]

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $9 156% upside
• Avg. target: $12.25 248% upside
• High target: $17 383% upside

4 analyst ratings

• positive: 4 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Raghuram Selvaraju 37% 1-year accuracy 116 / 310 met price target	184% upside $10	Buy Reiterated	20 Dec 2024
Cantor Fitzgerald Kristen Kluska 38% 1-year accuracy 40 / 105 met price target	383% upside $17	Overweight Initiated	17 Dec 2024
Leerink Partners Roanna Ruiz 43% 1-year accuracy 3 / 7 met price target	269% upside $13	Outperform Maintained	25 Oct 2024
JMP Securities Jason Butler 33% 1-year accuracy 13 / 40 met price target	156% upside $9	Market Outperform Reiterated	8 Oct 2024